CurrentArizona Complete HealthPolicy CP.MP.62

Clinical Policy: Hyperhidrosis Treatments

Medical necessity criteria and coding guidance for treatment of primary hyperhidrosis (iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy) for members/enrollees of Centene-affiliated health plans.

Policy Summary

PayerArizona Complete Health

PolicyClinical Policy: Hyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeCoding and criteria updatesadded ETS counseling requirement

Effective Date

Next Review Date

Key ActionObtain prior authorization when services meet medical necessity criteria and document diagnosis, failed conservative therapy, and counseling as applicable.

SourceLink

POLICY UPDATE CHANGES

Removed six month time frame requirement for trial of conservative management and removed certain CPT and ICD-10 codes.

Added criteria point III.I. requiring counseling on risks for ETS.

Updated criteria I.E.3. by removing (hyperhidrosis often improves pregnancy) and added epilepsy to Criteria I.E.5; multiple minor verbiage updates with no impact to criteria.

3Treatment categories

5Iontophoresis contraindications

>=55 bpmETS RHR threshold

miraDry

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Hyperhidrosis Treatments

Iontophoresis (initial therapy)

Covered when ALL of the following are met

I. Iontophoresis (medically necessary when all met): A. Diagnosis of primary hyperhidrosis; B. Development of medical complications, such as skin maceration with secondary skin infections, or a significant constant disruption of professional and/or social life due to excessive sweating (e.g., recurrent changing of clothes, affecting job/social function); C. Failed a trial of conservative management including adherent application of aluminum chloride hexahydrate (prescription Drysol) or topical agents have resulted in a severe rash; D. Has none of the following contraindications: 1. Cardiac pacemaker; 2. Cardiac arrhythmias; 3. Pregnancy; 4. Metal implants, depending on size and position (may divert the electric current); 5. Epilepsy.

Surgical excision (axillary)

Covered when ALL of the following are met

II. Surgical excision of axillary sweat glands: A. Meets all of the iontophoresis criteria in I.A. through I.E.; B. Has persistent and severe primary hyperhidrosis; C. Has failed one of the following: 1. Iontophoresis; 2. Trial of botulinum toxin.

Endoscopic thoracic sympathectomy (ETS)

Covered when ALL of the following are met

III. Endoscopic thoracic sympathectomy (ETS): A. Meets all of the iontophoresis criteria in I.A. through I.E.; B. Member/enrollee has a resting heart rate > 55 beats per minute; C. Hyperhidrosis symptoms started at an early age (usually < 16 years), and surgery is requested for a young member/enrollee (usually < 25 years of age); D. Body mass index < 28; E. Reports no sweating during sleep; F. Member/enrollee has no significant comorbidities; G. Member/enrollee has persistent and severe primary hyperhidrosis; H. Member/enrollee has failed one of the following: 1. Iontophoresis; 2. Trial of botulinum toxin for predominantly axillary hyperhidrosis; I. Member/enrollee has been counseled on risks of procedure.

Insufficient evidence / Not supported

IV. Other treatments: There is insufficient evidence in the published peer reviewed literature to support all other treatments for hyperhidrosis, including, but not limited to, microwave therapy or liposuction as the sole method of removing axillary sweat glands; miraDry is FDA approved for primary axillary hyperhidrosis but current evidence is limited in quantity and quality per NICE guidance and should be used only with special arrangements for governance, consent, and audit or research.

There is insufficient evidence in the published peer‑reviewed literature to support other treatments for hyperhidrosis as standard therapies. Examples explicitly noted include microwave therapy and liposuction as the sole method of removing axillary sweat glands. These approaches are not covered as routine treatments without special arrangements for governance or evaluation.

Transcutaneous microwave ablation (miraDry) is FDA‑approved for primary axillary hyperhidrosis but the evidence base is limited. Per NICE, current evidence on the safety and efficacy of transcutaneous microwave ablation for severe primary axillary hyperhidrosis is inadequate in quantity and quality, and this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

Coding and Clinical Thresholds

Referenced CPT CodesCPT

11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair.
11451	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair.
15877	Suction assisted lipectomy; trunk.
15878	Suction assisted lipectomy; upper extremity.
32664	Thoracoscopy, surgical; with thoracic sympathectomy.
97024	Application of a modality to 1 or more areas; diathermy (eg, microwave).
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes.

inv-08: Resting heart rate requirement for ETS

Resting heart rate threshold> 55 beats per minute

Context within ETS criteriaRequired as criterion III.B: member must have a resting heart rate > 55 bpm

Source guidanceApplies to candidacy for Endoscopic Thoracic Sympathectomy (ETS)

inv-09: Body mass index requirement for ETS

BMI threshold< 28

Context within ETS criteriaRequired as criterion III.D: member must have body mass index < 28

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required when criteria for iontophoresis, surgical excision, or endoscopic thoracic sympathectomy (ETS) apply. Submit a request before scheduling services when any of the following procedures are planned: iontophoresis (CPT 97033), ETS (CPT 32664), surgical excision of axillary sweat glands (CPTs 11450, 11451), or related procedures listed below. Authorization decisions rely on documentation that meets the Required Clinical Documentation and Step Therapy criteria.

Prior authorization required for iontophoresis (97033) when medically necessary criteria met
Prior authorization required for ETS (32664) when medically necessary criteria met
Prior authorization required for surgical excision (11450, 11451) when medically necessary criteria met

Step Therapy

Step Therapy / Required Trial

Conservative management must be attempted and documented prior to authorization of more invasive therapies. Specifically, members must have failed a trial of conservative measures including adherent application of aluminum chloride hexahydrate (prescription Drysol) or have experienced severe topical-agent rash precluding continued use. For surgical excision or ETS, the member must have failed one of the following: iontophoresis or a trial of botulinum toxin (for predominantly axillary hyperhidrosis).

Background and Context

Primary focal hyperhidrosis is idiopathic, excessive focal sweating most commonly affecting the axillae, palms, and soles. It is characterized by visible, excessive sweating that often begins at a young age and can cause significant social, occupational, and emotional impairment.

Primary focal hyperhidrosis is distinct from secondary hyperhidrosis, which results from medications or underlying medical conditions and is typically generalized or craniofacial; treatment for secondary causes targets the underlying disorder.

Clinical policy criteria for surgical options note that candidates for procedures such as endoscopic thoracic sympathectomy should have features consistent with primary focal hyperhidrosis (for example, early symptom onset, no sweating during sleep, persistent and severe symptoms) and must meet specified physiologic thresholds and prior‑therapy requirements before surgery is authorized.

Definitions

inv-15: Primary focal hyperhidrosis — definition

DefinitionVisible, excessive focal sweating (commonly axillae, palms, soles) of at least six months' duration without apparent cause

EtiologyIdiopathic; induced by sympathetic hyperactivity in selected areas and not associated with underlying disease

Common locationsAxillae (underarms), palms, and soles

inv-16: Secondary hyperhidrosis — definition

DefinitionExcessive sweating due to medications or underlying disease, usually generalized or craniofacial

Common causesMedications (e.g., tricyclic antidepressants, SSRIs) or conditions (e.g., febrile illnesses, diabetes, menopause)

Revision History

2025-11annual_reviewLatest

Annual review: removed phrase 'in response to heat exposure or exercise' from description; removed Criteria I.C.; removed six-month timeframe for trial of conservative management in Criteria I.D.; removed note under Criteria III. regarding standard line of medical therapy; coding and descriptions reviewed; references updated; reviewed by external specialist.

2024-11annual_review

Annual review: updated Criteria I.E.3 by removing parenthetical about pregnancy improvement; removed prior Criteria I.E.5 about cracked skin and added epilepsy to Criteria I.E.5; minor grammatical and wording updates across Criteria II and III; added diathermy to coding notation about insufficient evidence; references reviewed and updated.